A 6 Month Safety Extension Study of MBGS205

Status Completed

Clinical Trial Summary

Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)

Clinical Trial Description

This is a 6 months, active treatment, extension study, open to subjects who have completed full 24 weeks in Study MBGS205 (A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism [HH]).The main purpose of Study MBGS206 is to evaluate long term safety and efficacy parameters in subjects after 12 months exposure with BGS649. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02908074
Study type	Interventional
Source	Mereo BioPharma
Contact
Status	Completed
Phase	Phase 2
Start date	November 15, 2016
Completion date	November 21, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01438073` - Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling	Phase 1
Completed	`NCT01403532` - Sequential Therapy for Hypogonadotropic Hypogonadism	Phase 4
Recruiting	`NCT00456274` - Baselines in Reproductive Disorders	N/A
Terminated	`NCT05205837` - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial	Phase 4
Completed	`NCT05752591` - Hypothalamic-pituitary Dysfunction in Diabetes
Terminated	`NCT03118479` - Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)	Phase 1
Completed	`NCT02730169` - Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism	Phase 2
Completed	`NCT02110368` - Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions	Phase 3
Recruiting	`NCT01601171` - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed	`NCT01623570` - Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP	N/A
Terminated	`NCT00328926` - Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])	Phase 4
Completed	`NCT01438034` - Kisspeptin in the Evaluation of Delayed Puberty	Phase 1
Completed	`NCT04456296` - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism	Phase 4
Recruiting	`NCT00914823` - Kisspeptin Administration in the Adult	Phase 1
Terminated	`NCT01155518` - Hypogonadism in Young Men With Type 2 Diabetes	Phase 2
Completed	`NCT00697814` - Clomiphene in Males With Prolactinomas and Persistent Hypogonadism	Phase 2
Active, not recruiting	`NCT00351416` - Letrozole Treatment in Normal and GnRH Deficient Women	Phase 2/Phase 3
Recruiting	`NCT05971836` - The Molecular Basis of Inherited Reproductive Disorders
Recruiting	`NCT02705014` - Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome	N/A
Recruiting	`NCT04648969` - Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism	Phase 2